Terms: = Prostate cancer AND BCL7A, BCL7, 605, ENSG00000110987 AND Treatment
27 results:
1. Hsa_circ_0063329 inhibits prostate cancer growth and metastasis by modulating the miR-605-5p/tgif2 axis.
Lv D; Cen S; Yang S; Zou Z; Zhong J; Pan Z; Deng N; Li Y; Wu K; Wang J; Liu P
Cell Cycle; 2023 May; 22(9):1101-1115. PubMed ID: 36740902
[TBL] [Abstract] [Full Text] [Related]
2. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant prostate cancer.
Tu MM; Clemons M; Stober C; Jeong A; Vandermeer L; Mates M; Blanchette P; Joy AA; Aseyev O; Pond G; Fergusson D; Ng TL; Thavorn K
Curr Oncol; 2021 May; 28(3):1847-1856. PubMed ID: 34068083
[TBL] [Abstract] [Full Text] [Related]
3. MiR-501-3p promotes osteosarcoma cell proliferation, migration and invasion by targeting bcl7a.
Dai J; Lu L; Kang L; Zhang J
Hum Cell; 2021 Mar; 34(2):624-633. PubMed ID: 33415690
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of Deep Learning to Augment Image-Guided Radiotherapy for Head and Neck and prostate cancers.
Oktay O; Nanavati J; Schwaighofer A; Carter D; Bristow M; Tanno R; Jena R; Barnett G; Noble D; Rimmer Y; Glocker B; O'Hara K; Bishop C; Alvarez-Valle J; Nori A
JAMA Netw Open; 2020 Nov; 3(11):e2027426. PubMed ID: 33252691
[TBL] [Abstract] [Full Text] [Related]
5. Differences in Stage of cancer at Diagnosis, treatment, and Survival by Race and Ethnicity Among Leading cancer Types.
Zhang C; Zhang C; Wang Q; Li Z; Lin J; Wang H
JAMA Netw Open; 2020 Apr; 3(4):e202950. PubMed ID: 32267515
[TBL] [Abstract] [Full Text] [Related]
6. Detection of prostate cancer by Raman spectroscopy: A multivariate study on patients with normal and altered PSA values.
Correia NA; Batista LTA; Nascimento RJM; Cangussú MCT; Crugeira PJL; Soares LGP; Silveira L; Pinheiro ALB
J Photochem Photobiol B; 2020 Mar; 204():111801. PubMed ID: 31978674
[TBL] [Abstract] [Full Text] [Related]
7. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
[TBL] [Abstract] [Full Text] [Related]
8. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
Mahumud RA; Alam K; Dunn J; Gow J
PLoS One; 2019; 14(10):e0223658. PubMed ID: 31596899
[TBL] [Abstract] [Full Text] [Related]
9. Participation of the SMAD2/3 signalling pathway in the down regulation of megalin/LRP2 by transforming growth factor beta (TGF-ß1).
Cabezas F; Farfán P; Marzolo MP
PLoS One; 2019; 14(5):e0213127. PubMed ID: 31120873
[TBL] [Abstract] [Full Text] [Related]
10. Aggressive cancer Behavior of Latent Gleason Pattern 5 in prostatectomy Specimens.
Fujimura T; Fukuhara H; Yamada Y; Taguchi S; Sugihara T; Niimi A; Nakamura M; Nakagawa T; Igawa Y; Homma Y; Kume H
Anticancer Res; 2018 Nov; 38(11):6529-6535. PubMed ID: 30396982
[TBL] [Abstract] [Full Text] [Related]
11. Anticancer Activity of Anthopleura anjunae Oligopeptides in prostate cancer DU-145 Cells.
Wu ZZ; Ding GF; Huang FF; Yang ZS; Yu FM; Tang YP; Jia YL; Zheng YY; Chen R
Mar Drugs; 2018 Apr; 16(4):. PubMed ID: 29649141
[No Abstract] [Full Text] [Related]
12. Primary treatment Choice Over Time and Relative Survival of prostate cancer Patients: Influence of Age, Grade, and Stage.
Matthes KL; Limam M; Dehler S; Korol D; Rohrmann S
Oncol Res Treat; 2017; 40(9):484-489. PubMed ID: 28813713
[TBL] [Abstract] [Full Text] [Related]
13. prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
[TBL] [Abstract] [Full Text] [Related]
14. Risk Group and Death From prostate cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk prostate cancer.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
[TBL] [Abstract] [Full Text] [Related]
15. The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome.
Buttigliero C; Vana F; Bertaglia V; Vignani F; Fiori C; Osella G; Porpiglia F; Tucci M; Scagliotti GV; Berruti A
Endocrine; 2015 Sep; 50(1):223-30. PubMed ID: 25588772
[TBL] [Abstract] [Full Text] [Related]
16. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract] [Full Text] [Related]
17. Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the prostate cancer Registry.
Evans SM; Millar JL; Frydenberg M; Murphy DG; Davis ID; Spelman T; Bolton DM; Giles GG; Dean J; Costello AJ; Frauman AG; Kearns PA; Day L; Daniels C; McNeill JJ
BJU Int; 2014 Nov; 114(5):680-90. PubMed ID: 24128010
[TBL] [Abstract] [Full Text] [Related]
18. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
Mitsiades N
Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
[TBL] [Abstract] [Full Text] [Related]
19. The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
Lin GW; Yao XD; Ye DW; Zhu Y; Zhang SL; Dai B; Zhang HL; Shen YJ; Ma CG
Asian J Androl; 2012 Sep; 14(5):732-7. PubMed ID: 22902911
[TBL] [Abstract] [Full Text] [Related]
20. Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy.
Tollefson MK; Boorjian SA; Gettman MT; Rangel LJ; Bergstralh EJ; Karnes RJ
Urol Oncol; 2013 Nov; 31(8):1483-8. PubMed ID: 22578510
[TBL] [Abstract] [Full Text] [Related]
[Next]
